ENG
Thyroid Eye Disease Treatment Market Industry Overview, Size, Share, Growth Trends, Research Insights and Forecast (2025–2032)
Thyroid Eye Disease Treatment Market size was valued at USD 2.67 Billion in 2024 and the total Global Revenue Thyroid Eye Disease Treatment Market is expected to grow at a CAGR of 5.92% from 2025 to 2032, reaching nearly USD 4.23 Billion by 2032
Format : PDF | Report ID : SMR_2767
Thyroid Eye Disease Treatment Market Overview
Thyroid Eye Disease Treatment (TED) is a complex autoimmune-mediated inflammatory disorder of the orbit that is associated with a spectrum of signs and symptoms and varying levels of severity. Early diagnosis and initiation of appropriate treatment are imperative for preventing progression to severe disease and potential vision loss.
Better healthcare Sevice, improvement in autoimmune disorder remedy, and Good compliance percent are the expected elements to growth the boom of the global thyroid eye disease treatment market. Increase in studies and development activities and growing investment are some other factors which are expected to increase goal marketplace boom. Increasing synthetic tears and smooth eye drops to reduce dryness and supply brief remedy from pain globally is anticipated to sell market growth in the coming years.
Thyroid eye disease treatment is estimated to be greatly expanded in the market, due to the dominance of biological drugs, especially Tapezza (now under Amgen after the acquisition of Horizon therapy). North America remains the largest market due to the high adoption of remedies and favorable reimbursement policies, while Europe and the Asia-Pacific are emerging as high-growth areas with enhancements in healthcare. Prominent players such as Amgen, Roche, and Pfizer, including the next generation biologics and biosimilars, are actively developing novel therapy to address UNMET requirements in medium-to-serious thyroid eye disease treatments. Competitive landscape is marked by strategic cooperation, clinical trials for new immunosuppressants, and a change towards individual treatment approaches.
To get more Insights: Request Free Sample Report
Thyroid Eye Disease Treatment Market Dynamics
Increasing Prevalence of Thyroid Disorders to Drive the Thyroid Eye Disease Treatment Market
The growing international prevalence of thyroid issues, in particular Graves' disease, is a motive force of the Thyroid Eye Disease Treatment market. According to the World Health Organization, thyroid-related conditions have an impact on about 750 Million humans globally, with a large percentage of hyperthyroidism. The National Institute of Diabetes and Digestive and Kidney Disease notes that 1% of the US population suffers from hyperthyroidism, which outlines the patient base for the expanded patient treatment options.
Regulatory challenges in drug approval to Restrain the Thyroid Eye Disease Treatment Market
The new thyroid eye disease (TED) treatment is a complex and long process to secure regulatory approval, which often requires extensive clinical trials and rigorous security assessment. On average, U.S. The Food and Drug Administration (FDA) takes a time between 8 and 12 years to approve a new drug, with only 10% of the investigation therapy successfully reaches the market. According to the Tufts Center for the Study of Drug Development, it can obstruct the introduction of innovative remedies for a long time and increase growth cost, which may exceed USD 2.6 billion per medicine. In the TED treatment scenario, companies must navigate several regulatory obstacles, including strict phase III clinical testing requirements to display efficacy and security.
Increasing Focus on Pediatric Cases to Boost the Thyroid Eye Disease Treatment Market
Thyroid Eye Disease Treatment (TED) Treatment is not exclusive to adults. Children with graves’ disease are also susceptible, which create a possible market for pediatric-specific remedies. According to the Disease Control and Prevention Center (CDC), the U.S. About 0.02% of children are diagnosed with hyperthyroidism every year, in which TED is an important part in the risk of developing. However, current treatment options are mainly designed for adults, leaving the difference in pediatric care. Increasing awareness about TED in children presents an opportunity for pharmaceutical companies to develop age-appropriate remedies. Currently, data on pediatric TED circulation is limited, but studies suggest that adolescents display about 5% of TED symptoms of tombs. Developing specialized yoga’s, conducting pediatric clinical trials, and adjusting dosage strategies can help address this non-medical requirement. As soon as the initial diagnosis rate improves, the demand for child-friendly TED treatments is expected to increase, to open new avenues for innovation in the bioformacular sector.
CURRENT MEDICATION OPTIONS FOR THYROID EYE DISEASE TREATMENT IN MARKET
|
MEDICATION |
HOW IS MEDICATION GIVEN? |
WHAT DOES THIS MEDICINE IMPROVE? |
SIDE EFFECTS |
|
Selenium |
By mouth |
Mild eye symptoms |
High levels can cause diarrhea, nausea, brittle nails, irritability, and skin rashes |
|
Steroids |
Intravenous (injection) |
Swelling of the eyes |
Some people using this medication experience changes in mood, difficulty sleeping, and changes in blood pressure or blood sugar |
|
Teprotumumab |
Intravenous (infusion) |
Irritation and bulging of the eye May reduce the need for surgery |
Some people using this medication experience: high blood sugars, decreased hearing, gastro-intestinal symptoms, and muscle cramps. Cannot be used during pregnancy or breastfeeding |
Thyroid Eye Disease Treatment Market Segments
Based on route of administration, thyroid eye disease treatment market is divided a parental administration, and topical administration. Parental administration is the largest segment in the Thyroid Eye Disease Treatment market, due to widespread use of intravenous monoclonal antibody therapy such as Teprotumumab. The US Food and Drug Administration underlines the efficacy of the parently distributed biologics, which attains rapid symptoms relief and high bioavailability than other routes. Interior treatment is important for severe TED cases, especially in reducing proptosis and inflammation. The effectiveness and targeted action of Parental Administration jointly with its requirement for advanced therapy has strengthened its leading role in the market.
Based on end-use industry, thyroid eye disease treatment market is divided a hospital clinics, and other. Hospitals dominate the Thyroid Eye Disease Treatment market, which are due to their ability to provide extensive care tools, specialized treatment and surgical intervention for serious ted cases. According to the centers of Medicare and Medicate Services, hospitals have more than 60% health services, which are U.S. Hospitals also serve as key providers of biologic therapy such as Teprotumumab, which require administration by trained professionals. Ensuring their role and multi-clinic care in the management of complex Thyroid cases strengthens their position as the largest section in the market.
Thyroid Eye Disease Treatment Market Regional Analysis
North America holds the biggest part of the Thyroid Eye Disease Treatment market due to its well-established healthcare infrastructure, high prevalence of thyroid disorders and strong adoption of advanced treatments. The American Thyroid Association reports that 1 out of 8 women in the US will develop thyroid issues during their lifetime, many of which are thyroid-related. Additionally, the approval of targeted remedies such as Teprotumumab by the US Food and Drug Administration has inspired the regional market growth. The presence of major pharmaceutical companies, ongoing research funding and comprehensive awareness campaigns further strengthens the dominance of the field. U.S. And Canada is predicted to maintain strong performance due to health care expenses and progress in biological remedies, ensuring continuous growth
Thyroid Eye Disease Treatment Market Competitive Landscape
Dominance of major drug and biotechnology companies that focus on biologics and monoclonal antibody therapy. The North America carries with major players such as the therapeutics, Magen, Viridian therapeutics and Physics, which benefits from drugs approved by FDAs such as Teprotumumab. Europe takes advantage of strong R&D investment and regional regulatory approval, with firms such as Novartis, Sanofi, and GlaxoSmithKline. Asia-Pacific HanAll Biopharma, Dr. Reddy Laboratories is emerging as a high-development sector with companies such as laboratories, to expand the market through cost-effective treatments and increase patient awareness. The market is watching increasing competition due to targeted biologics, biosimilar and progress in personal medicine, while regulatory barriers and high growth costs remain significant obstacles to new entry.
|
Thyroid Eye Disease Treatment Market Scope |
|
|
Market Size in 2024 |
USD 2.67 Bn. |
|
Market Size in 2032 |
USD 4.23 Bn. |
|
CAGR (2024-2032) |
5.92 % |
|
Historic Data |
2019-2024 |
|
Base Year |
2024 |
|
Forecast Period |
2025-2032 |
|
Segments |
By Route of Administration Parental Administration Topical Administration |
|
By Distribution Hospital Pharmacy Online Pharmacy Retail Pharmacy |
|
|
By End Use Industry Hospital Clinics Other |
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Thyroid Eye Disease Treatment Market Key Players:
North America
- Horizon Therapeutics (United States)
- Amgen (United States)
- Pfizer (United States)
- Regeneron Pharmaceuticals (United States)
- Bristol-Myers Squibb (United States)
- Novartis (United States)
- Bausch Health (Canada)
Europe
- Roche (Switzerland)
- Novartis International (Switzerland)
- Merck KGaA (Germany)
- Sanofi (France)
- AstraZeneca (United Kingdom)
- GlaxoSmithKline (United Kingdom)
- Swedish Orphan Biovitrum - Sobi (Sweden)
- LEO Pharma (Denmark)
Asia Pacific
- Takeda Pharmaceutical (Japan)
- Daiichi Sankyo (Japan)
- Fosun Pharma (China)
- Sun Pharma (India)
- Dr. Reddy’s Laboratories (India)
- Samsung Bioepis (South Korea)
- CSL Limited (Australia)
Middle East & Africa
- Teva Pharmaceutical (Israel)
- Aspen Pharmacare (South Africa)
South America
- Eurofarma (Brazil)
- Aché Laboratórios (Brazil)
- Elea Phoenix (Argentina)
Frequently Asked Questions
The increasing prevalence of thyroid disorders, advancements in biological therapies, and the introduction of targeted treatments like Teprotumumab are the main growth drivers for the market.
North America leads the market due to its well-established healthcare infrastructure, high thyroid disease prevalence, and the early adoption of advanced treatments like Teprotumumab.
Regulatory challenges, high drug development costs, and lengthy approval processes (taking 8-12 years on average) pose significant hurdles for new TED treatments.
Targeted biologics and monoclonal antibodies, such as Teprotumumab, reduce inflammation and symptoms by focusing on immune response molecules like IL-6 and IGF-1 receptors.
1. Thyroid Eye Disease Treatment Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary
2. Global Thyroid Eye Disease Treatment Market: Competitive Landscape
2.1. Ecosystem Analysis
2.2. SMR Competition Matrix
2.3. Competitive Landscape
2.4. Key Players Benchmarking
2.4.1. Company Name
2.4.2. Business Segment
2.4.3. End-user Segment
2.4.4. Revenue (2024)
2.4.5. Company Locations
2.5. Market Structure
2.5.1. Market Leaders
2.5.2. Market Followers
2.5.3. Emerging Players
2.6. Mergers and Acquisitions Details
3. Thyroid Eye Disease Treatment Market: Dynamics
3.1. Thyroid Eye Disease Treatment Market Trends by Region
3.1.1. North America Thyroid Eye Disease Treatment Market Trends
3.1.2. Europe Thyroid Eye Disease Treatment Market Trends
3.1.3. Asia Pacific Thyroid Eye Disease Treatment Market Trends
3.1.4. Middle East and Africa Thyroid Eye Disease Treatment Market Trends
3.1.5. South America Thyroid Eye Disease Treatment Market Trends
3.2. Thyroid Eye Disease Treatment Market Dynamics
3.2.1. Global Thyroid Eye Disease Treatment Market Drivers
3.2.2. Global Thyroid Eye Disease Treatment Market Restraints
3.2.3. Global Thyroid Eye Disease Treatment Market Opportunities
3.2.4. Global Thyroid Eye Disease Treatment Market Challenges
3.3. PORTER’s Five Forces Analysis
3.4. PESTLE Analysis
4. Thyroid Eye Disease Treatment Market: Global Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032)
4.1. Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
4.1.1. Parental Administration
4.1.2. Topical Administration
4.2. Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
4.2.1. Hospital Pharmacy
4.2.2. Online Pharmacy
4.2.3. Retail Pharmacy
4.3. Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
4.3.1. Hospital
4.3.2. Clinics
4.3.3. Others
4.4. Thyroid Eye Disease Treatment Market Size and Forecast, by Region (2024-2032)
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. Middle East and Africa
4.4.5. South America
5. North America Thyroid Eye Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032)
5.1. North America Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
5.1.1. Parental Administration
5.1.2. Topical Administration
5.2. North America Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
5.2.1. Hospital Pharmacy
5.2.2. Online Pharmacy
5.2.3. Retail Pharmacy
5.3. North America Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
5.3.1. Hospital
5.3.2. Clinics
5.3.3. Others
5.4. North America Thyroid Eye Disease Treatment Market Size and Forecast, by Country (2024-2032)
5.4.1. United States
5.4.1.1. United States Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
5.4.1.1.1. Parental Administration
5.4.1.1.2. Topical Administration
5.4.1.2. United States Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
5.4.1.2.1. Hospital Pharmacy
5.4.1.2.2. Online Pharmacy
5.4.1.2.3. Retail Pharmacy
5.4.1.3. United States Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
5.4.1.3.1. Hospital
5.4.1.3.2. Clinics
5.4.1.3.3. Others
5.4.1.4. Canada Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
5.4.1.4.1. Parental Administration
5.4.1.4.2. Topical Administration
5.4.1.5. Canada Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
5.4.1.5.1. Hospital Pharmacy
5.4.1.5.2. Online Pharmacy
5.4.1.5.3. Retail Pharmacy
5.4.2. Canada Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
5.4.2.1.1. Hospital
5.4.2.1.2. Clinics
5.4.2.1.3. Others
5.4.3. Mexico
5.4.3.1. Mexico Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
5.4.3.1.1. Parental Administration
5.4.3.1.2. Topical Administration
5.4.3.2. Mexico Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
5.4.3.2.1. Hospital Pharmacy
5.4.3.2.2. Online Pharmacy
5.4.3.2.3. Retail Pharmacy
5.4.3.3. Mexico Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
5.4.3.3.1. Hospital
5.4.3.3.2. Clinics
5.4.3.3.3. Others
6. Europe Thyroid Eye Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032)
6.1. Europe Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.2. Europe Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.3. Europe Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4. Europe Thyroid Eye Disease Treatment Market Size and Forecast, by Country (2024-2032)
6.4.1. United Kingdom
6.4.1.1. United Kingdom Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.1.2. United Kingdom Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.1.3. United Kingdom Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4.2. France
6.4.2.1. France Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.2.2. France Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.2.3. France Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4.3. Germany
6.4.3.1. Germany Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.3.2. Germany Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.3.3. Germany Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4.4. Italy
6.4.4.1. Italy Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.4.2. Italy Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.4.3. Italy Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4.5. Spain
6.4.5.1. Spain Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.5.2. Spain Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.5.3. Spain Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4.6. Sweden
6.4.6.1. Sweden Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.6.2. Sweden Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.6.3. Sweden Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4.7. Austria
6.4.7.1. Austria Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.7.2. Austria Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.7.3. Austria Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
6.4.8.2. Rest of Europe Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
6.4.8.3. Rest of Europe Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7. Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032)
7.1. Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.2. Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.3. Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4. Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast, by Country (2024-2032)
7.4.1. China
7.4.1.1. China Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.1.2. China Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.1.3. China Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.2. S Korea
7.4.2.1. S Korea Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.2.2. S Korea Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.2.3. S Korea Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.3. Japan
7.4.3.1. Japan Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.3.2. Japan Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.3.3. Japan Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.4. India
7.4.4.1. India Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.4.2. India Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.4.3. India Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.5. Australia
7.4.5.1. Australia Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.5.2. Australia Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.5.3. Australia Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.6. Indonesia
7.4.6.1. Indonesia Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.6.2. Indonesia Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.6.3. Indonesia Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.7. Malaysia
7.4.7.1. Malaysia Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.7.2. Malaysia Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.7.3. Malaysia Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.8. Vietnam
7.4.8.1. Vietnam Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.8.2. Vietnam Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.8.3. Vietnam Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.9. Thailand
7.4.9.1. Thailand Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.9.2. Thailand Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.9.3. Thailand Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.10. Philippines
7.4.10.1. Philippines Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.10.2. Philippines Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.10.3. Philippines Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
7.4.11. Rest of Asia Pacific
7.4.11.1. Rest of Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
7.4.11.2. Rest of Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
7.4.11.3. Rest of Asia Pacific Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
8. Middle East and Africa Thyroid Eye Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032)
8.1. Middle East and Africa Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
8.2. Middle East and Africa Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
8.3. Middle East and Africa Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
8.4. Middle East and Africa Thyroid Eye Disease Treatment Market Size and Forecast, by Country (2024-2032)
8.4.1. South Africa
8.4.1.1. South Africa Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
8.4.1.2. South Africa Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
8.4.1.3. South Africa Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
8.4.2. GCC
8.4.2.1. GCC Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
8.4.2.2. GCC Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
8.4.2.3. GCC Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
8.4.3. Nigeria
8.4.3.1. Nigeria Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
8.4.3.2. Nigeria Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
8.4.3.3. Nigeria Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
8.4.4. Rest of ME&A
8.4.4.1. Rest of ME&A Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
8.4.4.2. Rest of ME&A Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
8.4.4.3. Rest of ME&A Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
9. South America Thyroid Eye Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Billion) (2024-2032)
9.1. South America Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
9.2. South America Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
9.3. South America Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
9.4. South America Thyroid Eye Disease Treatment Market Size and Forecast, by Country (2024-2032)
9.4.1. Brazil
9.4.1.1. Brazil Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
9.4.1.2. Brazil Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
9.4.1.3. Brazil Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
9.4.2. Argentina
9.4.2.1. Argentina Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
9.4.2.2. Argentina Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
9.4.2.3. Argentina Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
9.4.3. Rest of South America
9.4.3.1. Rest of South America Thyroid Eye Disease Treatment Market Size and Forecast, By Route of Administration (2024-2032)
9.4.3.2. Rest of South America Thyroid Eye Disease Treatment Market Size and Forecast, By Distribution (2024-2032)
9.4.3.3. Rest of South America Thyroid Eye Disease Treatment Market Size and Forecast, By End User Industry (2024-2032)
10. Company Profile: Key Players
10.1. Horizon Therapeutics (United States)
10.1.1. Company Overview
10.1.2. Business Portfolio
10.1.3. Financial Overview
10.1.4. SWOT Analysis
10.1.5. Strategic Analysis
10.1.6. Recent Developments
10.2. Amgen (United States)
10.3. Pfizer (United States)
10.4. Regeneron Pharmaceuticals (United States)
10.5. Bristol-Myers Squibb (United States)
10.6. Novartis (United States)
10.7. Bausch Health (Canada)
10.8. Roche (Switzerland)
10.9. Novartis International (Switzerland)
10.10. Merck KGaA (Germany)
10.11. Sanofi (France)
10.12. AstraZeneca (United Kingdom)
10.13. GlaxoSmithKline (United Kingdom)
10.14. Swedish Orphan Biovitrum - Sobi (Sweden)
10.15. LEO Pharma (Denmark)
10.16. Takeda Pharmaceutical (Japan)
10.17. Daiichi Sankyo (Japan)
10.18. Fosun Pharma (China)
10.19. Sun Pharma (India)
10.20. Dr. Reddy’s Laboratories (India)
10.21. Samsung Bioepis (South Korea)
10.22. CSL Limited (Australia)
10.23. Teva Pharmaceutical (Israel)
10.24. Aspen Pharmacare (South Africa)
10.25. Eurofarma (Brazil)
10.26. Aché Laboratórios (Brazil)
10.27. Elea Phoenix (Argentina)
11. Key Findings
12. Analyst Recommendations
13. Thyroid Eye Disease Treatment Market: Research Methodology
